Chalirmporn AtasilpPichai ChansriwongEkapob SirachainanThanyanan ReungwetwattanaApichaya PuangpetchSantirhat PrommasSuwannee SirilerttrakulBudsaba RerkarmnuaychokeSansanee WongwaisayawanChonlaphat SukasemFaculty of Medicine, Ramathibodi Hospital, Mahidol University2019-08-232019-08-232018-01-01Journal of Clinical Laboratory Analysis. Vol.32, No.1 (2018)10982825088780132-s2.0-85017550574https://repository.li.mahidol.ac.th/handle/20.500.14594/45295© 2017 Wiley Periodicals, Inc. Background: Irinotecan (CPT-11) is chemotherapy used mainly in the metastatic colorectal cancer. The purpose of this study was to develop and validate the LC-MS/MS for the simultaneous determination of CPT-11, SN-38, and SN-38G. Methods: A 100 μL of plasma was prepared after protein precipitation and analyzed on a C18 column using 0.1% acetic acid in water and 0.1% acetic acid in acetonitrile as mobile phases. The mass spectrometer worked with multiple reaction monitoring (MRM) in positive scan mode. The standard curves were linear on a concentration range of 5-10 000 ng/mL for CPT-11, 5-1000 ng/mL for SN-38, and 8-1000 ng/mL for SN-38G. Results: In this assay, the intra and interday precision consisted of ≤9.11% and ≤11.29% for CPT-11, ≤8.70% and 8.31% for SN-38, and ≤9.90 and 9.64% for SN-38G. Conclusion: This method was successfully used to quantify CPT-11, SN-38, and SN-38G and applied to a pharmacokinetic study.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyHealth ProfessionsMedicineArticleSCOPUS10.1002/jcla.22217